Table 1.
Number | % | |
---|---|---|
Sex | ||
Male | 92 | 76.0% |
Female | 29 | 24.0% |
Age (years) | ||
Median | 57 (27–79) | |
Cancer type | ||
Oral squamous cell carcinoma | 91 | 75.2% |
Oropharyngeal carcinoma | 23 | 19.0% |
P16 positive | 5 | 4.1% |
P16 negative | 18 | 14.9% |
Other cancer type | 7 | 5.8% |
PD-L1 | ||
CPS < 1 | 30 | 25.0% |
CPS ≥ 1 | 84 | 69.4% |
Unknown | 7 | 6.0% |
Number of prior lines of therapy* | ||
0 | 70 | NA |
≥1 | 60 | NA |
*9 patients were treated with both PD-1 antibody and EGFR antibody at different lines. NA, not applicable.